Private company
Kronos Bio, Inc.
American pharmaceutical preparations company, incorporated in Delaware.
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
-943.2%Operating margin3
-874.1%Net margin3
56.6%Revenue growth, 20243
-98.3%Return on equity3
-$65.4MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Research and development100¢$48.7M
Out of $9.8M in revenue.3 The company lost money this year.
Financial statements
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $04 | $6.3M3 | $9.8M3 | ||||
| Research and development | $5.0M5 | $13.4M6 | $43.2M6 | $112.9M7 | $93.7M4 | $84.5M3 | $48.7M3 |
| Operating income | -$6.6M5 | -$16.8M6 | -$58.0M6 | -$151.4M7 | -$137.1M4 | -$122.1M3 | -$92.9M3 |
| Interest | $76.0K5 | $3.0K6 | $3.9M6 | $06 | |||
| Income tax | $05 | $06 | $07 | $07 | $04 | $03 | $03 |
| Net income | -$6.7M5 | -$16.1M6 | -$88.4M6 | -$151.1M7 | -$133.2M4 | -$112.7M3 | -$86.1M3 |
| Earnings per share | -$2.767 | -$2.374 | -$1.953 | -$1.433 | |||
| Earnings per share (diluted) | -$2.767 | -$2.374 | -$1.953 | -$1.433 |
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Cash | $10.2M6 | $32.6M6 | $248.0M6 | $198.3M7 | $76.0M4 | $64.3M3 | $84.6M3 |
| Current assets | $93.3M5 | $419.8M6 | $347.6M7 | $244.3M4 | $178.8M3 | $115.2M3 | |
| Total assets | $102.7M5 | $512.0M6 | $391.5M7 | $294.9M4 | $213.3M3 | $124.4M3 | |
| Current liabilities | $2.7M5 | $12.9M6 | $13.6M7 | $21.5M4 | $24.7M3 | $15.3M3 | |
| Total liabilities | $3.0M5 | $46.4M6 | $46.4M7 | $50.4M4 | $54.2M3 | $36.8M3 | |
| Shareholders’ equity | -$7.3M6 | -$23.2M6 | $465.5M7 | $345.1M4 | $244.5M3 | $159.1M3 | $87.6M3 |
| Shares outstanding | 5.7M shares5 | 54.1M shares6 | 55.7M shares7 | 57.0M shares4 | 58.9M shares3 | 60.5M shares3 |
Leadership
Who has led Kronos Bio, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2025
- Chief executive officerDeborah Knobelman Jun 6, 2025 to now11
- Chief executive officerNorbert W. Bischofberger Oct 8, 2020 to Jun 6, 202512
- PresidentDeborah Knobelman Jun 6, 2025 to now11
- PresidentNorbert W. Bischofberger Oct 8, 2020 to Jun 6, 202512
- Chief financial officerDeborah Knobelman Jun 4, 2024 to now13
- Chief financial officerSandra Gardiner Sep 18, 2023 to Sep 18, 202314
- Chief financial officerYasir B. Al-Wakeel Oct 8, 2020 to Jul 7, 202315
- Chief operating officerBarbara Kosacz Oct 8, 2020 to now16
Board members and other officers (19)
- SR VP, CORP OPERATIONS & LEGALAllison Frisbee Feb 23, 2024 to now17
- SR VP, RESEARCH & DEVELOPMENTCharles Y. Lin Feb 23, 2024 to now18
- SR VP, CLINICAL SCIENCEElizabeth A. Olek Feb 23, 2024 to now19
- Chief Scientific OfficerChristopher Dinsmore Oct 8, 2020 to now20
- Chief Medical Officer & VPJorge Dimartino Oct 8, 2020 to now21
- Board memberKatherine Stultz V. Apr 11, 2023 to now22
- Board memberRoger D. Dansey Apr 24, 2023 to now23
- Board memberBacker Marianne De Jan 27, 2021 to Jun 26, 202324
- Board memberTaiyin Yang Mar 26, 2021 to now25
- Board memberRoshawn A. Blunt Nov 15, 2021 to now26
- Board memberArie Belldegrun Oct 8, 2020 to now27
- Board memberDavid M. Tanen Oct 8, 2020 to now28
- Board memberElena Ridloff Oct 8, 2020 to now29
- Board memberJakob Loven Oct 8, 2020 to Apr 20, 202130
- Board memberJoshoa A. Kazam Oct 8, 2020 to now31
- Board memberNorbert W. Bischofberger Oct 8, 2020 to now12
- Board memberOtello Stampacchia Oct 8, 2020 to Jun 29, 202232
- Board memberRebecka Belldegrun Oct 8, 2020 to Oct 16, 202033
- General counselBarbara Kosacz Oct 8, 2020 to now16
Timeline
Filings
204 filings to the SEC since October 2021: 6 annual reports, 13 quarterly reports, 46 major events, 91 insider forms, 13 large holders, 35 other. The latest 20:
- Jun 30, 202515-12G EDGAR
- Jun 23, 2025EFFECT EDGAR
- Jun 20, 20254 EDGAR
- Jun 20, 20254 EDGAR
- Jun 20, 20254 EDGAR
- Jun 20, 20254 EDGAR
- Jun 20, 20254 EDGAR
- Jun 20, 20254 EDGAR
- Jun 20, 20254 EDGAR
- Jun 20, 20254 EDGAR
- Jun 20, 20254 EDGAR
- Jun 20, 20254 EDGAR
- Jun 20, 2025SC 14D9/A SOLICITATION/RECOMMENDATION STATEMENT EDGAR
- Jun 20, 20258-K CURRENT REPORT EDGAR
- Jun 20, 2025S-8 POS EDGAR
- Jun 20, 2025S-8 POS EDGAR
- Jun 20, 2025S-8 POS EDGAR
- Jun 20, 2025S-8 POS EDGAR
- Jun 20, 2025S-8 POS EDGAR
- Jun 20, 2025POS AM EDGAR
The 204 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 13 such filings since October 2021, the latest 10:
- Jun 20, 2025SCHEDULE 13D/A
- Nov 14, 2024SC 13G/A
- Jul 2, 2024SC 13D/A
- Jun 12, 2024SC 13D/A
- Nov 27, 2023SC 13D
- Feb 13, 2023SC 13G/A
- Feb 13, 2023SC 13G/A
- Feb 9, 2023SC 13G/A
- Feb 17, 2022SC 13G/A
- Feb 17, 2022SC 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22SEC EDGARKatherine Stultz V., Board member
- 23SEC EDGARRoger D. Dansey, Board member
- 24SEC EDGARBacker Marianne De, Board member
- 25SEC EDGARTaiyin Yang, Board member
- 26SEC EDGARRoshawn A. Blunt, Board member
- 27SEC EDGARArie Belldegrun, Board member
- 28SEC EDGARDavid M. Tanen, Board member
- 29SEC EDGARElena Ridloff, Board member
- 30SEC EDGARJakob Loven, Board member
- 31SEC EDGARJoshoa A. Kazam, Board member
- 32SEC EDGAROtello Stampacchia, Board member
- 33SEC EDGARRebecka Belldegrun, Board member